MX351288B - Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta. - Google Patents

Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta.

Info

Publication number
MX351288B
MX351288B MX2014009298A MX2014009298A MX351288B MX 351288 B MX351288 B MX 351288B MX 2014009298 A MX2014009298 A MX 2014009298A MX 2014009298 A MX2014009298 A MX 2014009298A MX 351288 B MX351288 B MX 351288B
Authority
MX
Mexico
Prior art keywords
indazole
disorders
glycogen synthase
synthase kinase
carboxamide compounds
Prior art date
Application number
MX2014009298A
Other languages
English (en)
Other versions
MX2014009298A (es
Inventor
Alessandra Alisi Maria
Cazzolla Nicola
Furlotti Guido
Ombrato Rosella
Mancini Francesca
Garofalo Barbara
Magaro Gabriele
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of MX2014009298A publication Critical patent/MX2014009298A/es
Publication of MX351288B publication Critical patent/MX351288B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de 1H-indazol-3-carboxamida como inhibidores de glucógeno sintasa quinasa 3 beta La presente invención se refiere a los compuestos de 1H-indazol-3-carboxamida para utilizarse como inhibidores de glucógeno sintasa quinasa 3 beta (GSK-3ß) y a su uso en el tratamiento de trastornos relacionados con GSK-3ß tales como, por ejemplo, (i) trastornos de resistencia a insulina; (ii) enfermedades neurodegenerativas; (iii) trastornos de humor; (iv) trastornos esquizofrénicos; (v) trastornos cancerígenos; (vi) inflamación, (vii) trastornos de abuso de sustancias; y (viii) epilepsias.
MX2014009298A 2012-02-21 2013-02-08 Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta. MX351288B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12156298 2012-02-21
PCT/EP2013/052523 WO2013124169A1 (en) 2012-02-21 2013-02-08 Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Publications (2)

Publication Number Publication Date
MX2014009298A MX2014009298A (es) 2014-10-14
MX351288B true MX351288B (es) 2017-10-09

Family

ID=47710141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009298A MX351288B (es) 2012-02-21 2013-02-08 Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta.

Country Status (27)

Country Link
US (2) US9163013B2 (es)
EP (1) EP2817301B1 (es)
JP (1) JP6285873B2 (es)
KR (1) KR102101702B1 (es)
CN (1) CN104080781B (es)
AR (1) AR090085A1 (es)
AU (1) AU2013224313B2 (es)
BR (1) BR112014018657B1 (es)
CA (1) CA2860466C (es)
CY (1) CY1117467T1 (es)
DK (1) DK2817301T3 (es)
EA (1) EA026952B1 (es)
ES (1) ES2564033T3 (es)
GE (1) GEP201606552B (es)
HK (1) HK1203931A1 (es)
HR (1) HRP20160124T1 (es)
HU (1) HUE027445T2 (es)
IL (1) IL233825A (es)
MX (1) MX351288B (es)
PL (1) PL2817301T3 (es)
PT (1) PT2817301E (es)
RS (1) RS54539B1 (es)
SG (2) SG11201403788VA (es)
SI (1) SI2817301T1 (es)
SM (1) SMT201600054B (es)
UA (1) UA113189C2 (es)
WO (1) WO2013124169A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2817301T1 (sl) * 2012-02-21 2016-03-31 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A Uporaba 1H-indazol-3-karboksamidnih spojin kot inhibitorjev glikogen sintaza-kinaze-3beta
EP3190889B1 (en) * 2014-09-03 2021-11-17 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
WO2017093157A1 (en) * 2015-11-30 2017-06-08 Basilea Pharmaceutica Ag Piperidine, pyrrolidine and 2-oxo-1,3-oxazinane derivatives as inhibitors of bacterial efflux-pumps for the treatment of microbial infections
ES2913929T3 (es) * 2016-06-08 2022-06-06 Glaxosmithkline Ip Dev Ltd Compuestos químicos como inhibidores de la ruta de ATF4
KR20210005863A (ko) * 2018-05-07 2021-01-15 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 글리코겐 합성효소 키나아제 3 베타 억제제로서 1h-인다졸-3-카복사마이드 화합물
CN117186027B (zh) * 2023-09-11 2024-04-19 上海蓝木化工有限公司 一种糖原合酶激酶-3抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680453B2 (en) 1992-11-05 1997-07-31 Smithkline Beecham Plc Piperidine derivatives as 5-HT4 receptor antagonists
WO1996038420A1 (fr) 1995-05-31 1996-12-05 Nisshin Flour Milling Co., Ltd. Derives de l'indazole a groupe amino monocyclique
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
UA99927C2 (uk) 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US7947728B1 (en) * 2009-11-11 2011-05-24 Hoffmann-La Roche Inc. Indole and indazole analogs as glycogen synthase activators
US9611249B2 (en) 2012-02-12 2017-04-04 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
SI2817301T1 (sl) * 2012-02-21 2016-03-31 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A Uporaba 1H-indazol-3-karboksamidnih spojin kot inhibitorjev glikogen sintaza-kinaze-3beta

Also Published As

Publication number Publication date
AR090085A1 (es) 2014-10-15
US20140378455A1 (en) 2014-12-25
SI2817301T1 (sl) 2016-03-31
EP2817301B1 (en) 2015-12-23
EP2817301A1 (en) 2014-12-31
KR20140122725A (ko) 2014-10-20
JP6285873B2 (ja) 2018-02-28
AU2013224313A1 (en) 2014-07-17
UA113189C2 (xx) 2016-12-26
CY1117467T1 (el) 2017-04-26
US9700551B2 (en) 2017-07-11
CA2860466C (en) 2020-02-18
HK1203931A1 (zh) 2015-11-06
AU2013224313A8 (en) 2014-09-18
KR102101702B1 (ko) 2020-04-20
MX2014009298A (es) 2014-10-14
BR112014018657A2 (es) 2017-06-20
BR112014018657A8 (pt) 2017-07-11
IL233825A0 (en) 2014-09-30
DK2817301T3 (en) 2016-03-14
HUE027445T2 (en) 2016-09-28
SG11201403788VA (en) 2014-08-28
SMT201600054B (it) 2016-04-29
ES2564033T3 (es) 2016-03-17
SG10201701171TA (en) 2017-04-27
GEP201606552B (en) 2016-10-10
CA2860466A1 (en) 2013-08-29
HRP20160124T1 (hr) 2016-03-11
AU2013224313B2 (en) 2017-03-30
PL2817301T3 (pl) 2016-05-31
CN104080781B (zh) 2016-05-11
EA026952B1 (ru) 2017-06-30
IL233825A (en) 2017-03-30
PT2817301E (pt) 2016-03-14
BR112014018657B1 (pt) 2022-08-02
EA201491448A1 (ru) 2014-11-28
WO2013124169A1 (en) 2013-08-29
JP2015506995A (ja) 2015-03-05
RS54539B1 (en) 2016-06-30
US20160045485A1 (en) 2016-02-18
CN104080781A (zh) 2014-10-01
US9163013B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
MX351287B (es) Compuestos de 1h-indazol-3-carboxamida como inhibidores de glucogeno sintasa quinasa 3 beta.
MX351288B (es) Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta.
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
MX2015007921A (es) Compuestos heterociclicos novedosos como inhibidores de bromodominio.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX2014013090A (es) Derivados de pirrolotriazinona.
WO2012170827A3 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
PH12014501581A1 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
NZ630615A (en) Thiadiazolidinediones as gsk-3 inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX364859B (es) Derivados de imidazopirazinona.
MX366140B (es) Derivados de urea de piperidinas.
EP2576536A4 (en) INHIBITORS OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE
MX348147B (es) Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer.
MX369389B (es) Apoaecuorina para usarse en aliviar un síntoma asociado con esclerosis múltiple en un sujeto.
MX2015016760A (es) Derivados de ftalazina.
MY159995A (en) Pyrimidinyl indole compounds

Legal Events

Date Code Title Description
FG Grant or registration